PCI Biotech Holding Past Earnings Performance
Past criteria checks 0/6
PCI Biotech Holding's earnings have been declining at an average annual rate of -16.8%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 13.6% per year.
Key information
-16.8%
Earnings growth rate
-7.8%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -13.6% |
| Return on equity | -115.7% |
| Net Margin | -1,545.9% |
| Next Earnings Update | 17 Feb 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How PCI Biotech Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 5 | -73 | 17 | 61 |
| 30 Jun 22 | 5 | -84 | 16 | 73 |
| 31 Mar 22 | 6 | -88 | 17 | 77 |
| 31 Dec 21 | 6 | -88 | 21 | 72 |
| 30 Sep 21 | 7 | -90 | 19 | 72 |
| 30 Jun 21 | 7 | -90 | 18 | 74 |
| 31 Mar 21 | 7 | -100 | 18 | 77 |
| 31 Dec 20 | 7 | -72 | 14 | 76 |
| 30 Sep 20 | 8 | -71 | 18 | 76 |
| 30 Jun 20 | 8 | -64 | 16 | 74 |
| 31 Mar 20 | 9 | -61 | 14 | 82 |
| 31 Dec 19 | 9 | -89 | 15 | 83 |
| 30 Sep 19 | 10 | -68 | 15 | 73 |
| 30 Jun 19 | 10 | -62 | 14 | 64 |
| 31 Mar 19 | 10 | -43 | 14 | 44 |
| 31 Dec 18 | 10 | -35 | 14 | 40 |
| 30 Sep 18 | 10 | -46 | 13 | 43 |
| 30 Jun 18 | 10 | -48 | 14 | 44 |
| 31 Mar 18 | 10 | -48 | 13 | 45 |
| 31 Dec 17 | 10 | -43 | 13 | 41 |
| 30 Sep 17 | 10 | -34 | 10 | 35 |
| 30 Jun 17 | 10 | -33 | 8 | 36 |
| 31 Mar 17 | 10 | -35 | 6 | 40 |
| 31 Dec 16 | 10 | -32 | 4 | 39 |
| 30 Sep 16 | 11 | -34 | 4 | 41 |
| 30 Jun 16 | 11 | -34 | 4 | 41 |
| 31 Mar 16 | 10 | -31 | 4 | 38 |
| 31 Dec 15 | 10 | -32 | 4 | 39 |
Quality Earnings: PCIBO is currently unprofitable.
Growing Profit Margin: PCIBO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCIBO is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare PCIBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCIBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: PCIBO has a negative Return on Equity (-115.69%), as it is currently unprofitable.